PET Imaging and Bariatric Surgery

This study has been completed.
Information provided by (Responsible Party):
Julia P.Dunn,MD, Vanderbilt University Identifier:
First received: December 2, 2008
Last updated: December 12, 2015
Last verified: March 2011
The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2) and other studies have shown that obese people have less of these. We propose that low DRD2 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Condition Intervention
Obesity, Morbid
Drug: F-18 (fallypride)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PET Imaging and Bariatric Surgery

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • DRD2 density changes after bariatric surgery [ Time Frame: 6-12 weeks ]

Secondary Outcome Measures:
  • DRD2 density will change after very low calorie diet [ Time Frame: 9-11 days ]

Biospecimen Retention:   Samples With DNA
plasma and serum

Estimated Enrollment: 10
Study Start Date: January 2007
Study Completion Date: June 2012
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: F-18 (fallypride)
    Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
BMI greater than 35, ages 18-60, pending weight loss surgery

Inclusion Criteria:

  • Ages 18-60 years
  • BMI equal to or greater than 40, or equal to or greater than 35 if there are 2 or more co-morbidities
  • Weight less than 350 pounds

Exclusion Criteria:

  • History of substance abuse,including but not limited to alcohol, cocaine, marijuana, heroin, nicotine
  • History of psychiatric disorders
  • Use of any antidepressants or psychotropics in the past 12 months
  • Diabetes Mellitis
  • Positive pregnancy test
  • Any condition felt by the PI or co-investigators to interfere with the individual's ability to complete the study
  • Subjects on medications for the last 3 months, such as sibutramine, which could affect the quality of the study, as determined by the PI
  • Inability to travel to Nashville, TN four times
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00801827

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Julia P Dunn, MD Vanderbilt University Medical Center
Study Director: Robert M Kessler, MD Vanderbilt University Medical Center
  More Information

Responsible Party: Julia P.Dunn,MD, Physician, Vanderbilt University Identifier: NCT00801827     History of Changes
Other Study ID Numbers: IRB#061246 
Study First Received: December 2, 2008
Last Updated: December 12, 2015

Keywords provided by Vanderbilt University:
PET imaging

Additional relevant MeSH terms:
Obesity, Morbid
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on January 24, 2017